Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSK | P41240 | 5/20 | 0.60 |
| ▸ | MAP3K20 | Q9NYL2 | 5/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.53 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.53 |
| ▸ | ABL2 | P42684 | 1/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286190 | 1.00 | CSK (0.60) | CSKMAP3K20MAPK14MAP3K7MAP4K2 | |
| SCHEMBL12518518 | 0.87 | CSK (0.57) | CSKMAP3K20MAPK14MAP3K7MAP4K2 | |
| SCHEMBL16581650 | 0.78 | CSK (0.60) | CSKMAP3K20MAPK14MAP3K7MAP4K2 | |
| SCHEMBL26882912 | 0.76 | MAPK14 (0.77) | CSKMAP3K20MAPK14MAP3K7MAP4K2 | |
| SCHEMBL16581560 | 0.74 | MAPK14 (0.76) | CSKMAP3K20MAPK14MAP3K7MAP4K2 | |
| SCHEMBL2281315 | 0.70 | CSK (0.36) | CSKMAP3K20MAPK14MAP3K7MAP4K2 | |
| SCHEMBL2281321 | 0.70 | CSK (0.36) | CSKMAP3K20MAPK14MAP3K7MAP4K2 | |
| SCHEMBL16588527 | 0.70 | PRKCI (0.59) | CSKMAP3K20MAPK14AXLPRKCI | |
| SCHEMBL19986926 | 0.66 | CSK (0.41) | CSKMAP3K20MAPK14MAP3K7MAP4K2 | |
| SCHEMBL12132608 | 0.65 | TSHR (0.46) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2519517-A2 | TYPE II RAF KINASE INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011090738-A2 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090738-A2 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | CSK 174/4885MAP3K20 6/4885MAPK14 182/4885 |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CSK 174/4885MAP3K20 6/4885MAPK14 182/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CSK 174/4885MAP3K20 6/4885MAPK14 182/4885 |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CSK 174/4885MAP3K20 6/4885MAPK14 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.